June 15 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES FDA ACKNOWLEDGEMENT OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR METABLOK (LSALT PEPTIDE)
* ARCH BIOPARTNERS - FDA ACKNOWLEDGEMENT ENABLES CO TO INITIATE PHASE II TRIAL IN U.S. TO PREVENT LUNG, KIDNEY ORGAN INJURY IN COVID-19 PATIENTS
* ARCH BIOPARTNERS - EXPECTS TO BEGIN PHASE II TRIAL TO PREVENT ACUTE LUNG, KIDNEY ORGAN IN COVID-19 PATIENTS BEFORE END OF SUMMER, 2020
* ARCH BIOPARTNERS INC - PRIMARY ENDPOINT OF PHASE II TRIAL WAS EXPANDED TO A COMPOSITE THAT INCLUDES PREVENTION OF ARDS AND AKI